

Curriculum Vitae

Name	Hark Kyun Kim	
Nationality	Korean	
Education	1985-1991 1996-2000	M.D., Seoul National University College of Medicine, Korea Ph.D., Seoul National University College of Medicine, Korea
Postgraduate	1994-1999	Internship and Residency (Internal Medicine), Seoul National University Hospital
Fellowship	1999-2000 2000-2001 2005-2009	Clinical Fellow (Medical Oncology/Hematology), Seoul National University Hospital Fellow, Genetics Division, Research Institute of National Cancer Center, Japan CRTA Fellow, Laboratory of Cancer Biology and Genetics, NCI, Bethesda, MD
Positions	2001-Present 2001-Present 2014-Present	Staff Medical Oncologist, Hospital of National Cancer Center, Korea Researcher, Biomolecular Function Research Branch, Research Institute of National Cancer Center, Korea Adjunct Professor, Graduate School of Cancer Science & Policy, Korea
Awards	2006: NCI Director's Innovation Award (Career Development) 2007: NCI Center for Cancer Research Federal Technology Transfer Award 2008: NIH Fellow Award for Research Excellence 2008: NCI Center for Cancer Research Federal Technology Transfer Award 2009: Merit Award, Annual Meeting of American Society of Clinical Oncology 2015: Academy Award, Annual Meeting of Korean Cancer Society	
Patents	1. 질량분석패턴을 이용한 원발성간내담도암 및 전이성간암의 감별법: 국내등록10-1408217 2. 인지질을 이용한 암의 진단 방법: 국내등록10-1389382 3. 지질 프로파일을 이용한 비소세포성 폐암의 조직학적 분류를 위한 정보를 제공하는 방법: 국내등록 10-1384693 4. 면역치료 및 위암치료제에 대한 효능 및 독성평가를 위한 마우스 위암세포주: 등록PCT/KR2014/002760 5. 지질발현분석을 이용하여 신장암을 진단하는 방법: 국내출원 10-2014-0061542 6. 마이크로RNA 프로파일을 이용한 간내 선암의 원발부위 예측방법: 국내출원 10-2014-0066145	

Selected publications

Park JW, Park DM, Kim DY, **Kim HK**. Sca-1 enriches for a cancer stem cell-like subpopulation in mouse gastric cancer. *Stem Cells* 2016 Feb 11. Epub

Park JW, Park DM, Choi BK, Kwon B, Seong JK, Green JE, Kim DY, **Kim HK**. Establishment and characterization of metastatic gastric cancer cell lines from murine gastric adenocarcinoma lacking Smad4, p53, and E-cadherin. *Mol Carcinogenesis* 2015 Nov;54(11)

Kim HK, Green JE. Review: Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents. *Pharmacogenomics*.2014;15(3):375-84.

Park JW, Jang SH, Park DM, Lim NJ, Deng C, Kim DY, Green JE, **Kim HK**. Loss of E-cadherin and Smad4 cooperate to promote the development and metastasis of diffuse-type gastric adenocarcinoma. *Mol Cancer Res* 2014 Aug;12(8):1088-99

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014 Sep 11;513(7517):202-9

Jang SH, Park JW, Kim HR, Seong JK, **Kim HK**. ADRM1 gene amplification is a candidate driver for metastatic gastric cancers. *Clin Exp Metastasis*. 2014 Aug;31(6):727-33

Park JW, Paik NS, **Kim HK**. Preclinical Efficacy Testing for Stomach and Liver Cancers using a Hollow Fiber Assay. *Cancer Res Treat* 2014 Apr;46(2):186-93

Ahn G, Park DM, Park JW, Cho JY, Rhee SJ, Kim HY, Lee DS, Jang IJ, **Kim HK**. Development and validation of a microfluidic chip-based nano-liquid chromatography-triple quadrupole tandem mass spectrometry method for a sensitive and reliable quantification of 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma. *Anal Bioanal Chem*. 2013 Dec;405(30):9817-24.

Lee GK, Lee HS, Park YS, Lee JH, Lee SC, Lee JH, Lee SJ, Shanta SR, Park HM, Kim HR, Kim IH, Kim YH, Zo JI, Kim KP, **Kim HK**. Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. *Lung Cancer*. 2012 May;76(2):197

Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A, Green JE. Three-gene Predictor of Clinical Outcome for Gastric Cancer Patients Treated with Chemotherapy. *Pharmacogenomics J*. 2012 Apr;12(2):119

Kang HS, Lee SC, Park YS, Jeon YE, Lee JH, Jung SY, Park IH, Jang SH, Park HM, Yoo CW, Park SH, Han SY, Kim KP, Kim YH, Ro JS, **Kim HK**. Protein and lipid profiles classify breast cancers according to the intrinsic subtype. *BMC Cancer*. 2011 Oct 27;11:465

Kim CH, **Kim HK**, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE. RNA signature associated with outcome of gastric cancer patients following chemotherapy. *BMC Med Genomics*. 2011 Nov 23;4:79

Kim HK, Kim J, Korolevich S, Kim CH, Munroe D, Green JE. Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection. *BMC Med Genomics*. 2011 Jun 2;4:48.

Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, Green JE. A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients. *PLOS ONE* 6;2:e16694, 2011

Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. *J Proteome Res* 2010 Aug; 9(8): 4123.

임상시험 (Role: Principal investigator)

간전이를 동반한 대장암 또는 위암 환자를 대상으로 한 Ad5CRT정맥투여의 최대내약용량(MTD) 결정 및 안전성 평가를 위한 제 1상 임상시험 2014.8.1 ~ present
표준요법에 실패한 진행성 고형암 환자 대상 NOV120401(CKD-516정)의 안전성, 내약성 및 약동학적 특성을 평가하기 위한 제 1상 임상시험 2015.4.1 ~ present
전이성 진행성 위암에서의 도세탁셀/TS-1 의 Ib/II 상 임상시험 2004-9-1~ 2006-6-31
국소진행성 위암에서의 도세탁셀/시스플라틴 선행화학요법의 무작위배정2상연구 2003-1-1~ 2005-12-31
전이성 위암에서의 2차요법으로의 docetaxel/irinotecan 의 2 상 임상시험 2003-1-1~ 2004-12-31
전이성 위암에서의 low-dose docetaxel/fluorouracil/cisplatin 의 2 상 임상시험 2002-1-1~ 2003-12-31
전이성 위암에서의 Weekly docetaxel/capecitabine 의 2 상 임상시험 2001-12-1~ 2003-5-31

정부수탁연구과제

암환자의 진단 및 치료반응 예측을 위한 통합 질량분석시스템 개발 및 임상검증 (미래창조과학부: 세부과제책임자: 2009-2014)
위암의 생분자시그너처 동정 (미래창조과학부: 세부과제책임자: 2012-2015)
단백유전체 기반 표적치료 (국립암센터 기관고유사업: 연구책임자: 2014-)
위암의 종양유전자 및 종양억제유전자의 기능적 검증 (국립암센터 기관고유사업: 연구책임자 2015-)

민간수탁연구과제

위암의 효능예측인자 발굴을 위한 전임상연구 (연구책임자 2015-)